Latest Breaking News On - John brancaccio - Page 1 : comparemela.com

Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday? - Hepion Pharmaceuticals (NASDAQ:HEPA)

Updates on Hepion Pharmaceuticals' ASCEND-NASH Trial, now in wind-down phase. Explore insights into Phase 2b study progression and strategic alternatives.

Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?

Friday, Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) said it has begun winding down activities in its ASCEND-NASH Trial while continuing to explore strategic alternatives, as announced in December 2023. ASCEND-NASH is a Phase 2b, randomized, multicenter, double-blinded study with the first patient screened in August 2022 to evaluate the safety and efficacy of rencofilstat dosed for 12 months, with a target enrollment of 336 subjects. Enrollment was paused in April 2023, with 151 subjects randomized

Hepion ends Phase 2 study for NASH drug due to cash restraints (NASDAQ:HEPA)

Hepion Pharmaceuticals (HEPA) Winds Down Activities in Phase 2b 'ASCEND-NASH' Trial

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial